PTPN11 and cancer: To verify the possibility of SHP-2 inhibitor as an anti-ALV-J drug, SHP099, an allosteric inhibitor for SHP-2, was selected, which is famous for its high specificity, low toxicity, and high efficiency in cancer therapy [16].